Avidity Biosciences (RNA) Expected to Release Earnings on Thursday

Avidity Biosciences (NASDAQ:RNA) is expected to be announcing its Q3 2026 resultson Thursday, November 12th. Analysts expect the company to post earnings of ($0.8109) per share and revenue of $15.00 million for the quarter. Investors can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.

Avidity Biosciences (NASDAQ:RNA) last issued its quarterly earnings results on Thursday, August 13th. The biotechnology company reported ($1.18) earnings per share for the quarter, topping the consensus estimate of ($1.42) by $0.24. The firm had revenue of $3.00 million during the quarter, compared to analysts’ expectations of $0.67 million. On average, analysts expect Avidity Biosciences to post ($4.45) EPS for the current fiscal year and ($6.69) EPS for the next fiscal year.

Avidity Biosciences Trading Up 0.5%

RNA opened at $8.38 on Tuesday. The company has a market cap of $143.38 million and a price-to-earnings ratio of -3.90. The stock has a fifty day simple moving average of $9.14 and a two-hundred day simple moving average of $19.55. Avidity Biosciences has a 12-month low of $7.49 and a 12-month high of $16.77.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on RNA shares. Roth Capital initiated coverage on shares of Avidity Biosciences in a research report on Thursday, October 22nd. They issued a “buy” rating and a $15.00 target price on the stock. Weiss Ratings upgraded shares of Avidity Biosciences from a “sell (e-)” rating to a “sell (e)” rating in a research note on Monday, August 3rd. Finally, HC Wainwright lowered their price target on shares of Avidity Biosciences from $25.00 to $20.00 and set a “buy” rating for the company in a research report on Wednesday, October 28th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $40.80.

About Avidity Biosciences

Avidity Biosciences, Inc is a biotechnology company focused on developing RNA-based medicines for genetic diseases. The company’s approach is designed to address conditions that are difficult to treat with conventional oligonucleotide therapies, including diseases affecting skeletal muscle.

Avidity’s proprietary AOC (antibody oligonucleotide conjugate) platform combines monoclonal antibodies with oligonucleotide-based medicines. The antibody component is intended to help deliver the therapeutic payload to specific tissues, while the oligonucleotide component is designed to modify or regulate disease-related RNA.